Health Care • Medical Specialities
$251.82 ▼ -1.10
(-0.43%)
MKT CAP: $27.83B • VOL: 920.0K
52W L $171 52W H $257
DGX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $11.04B | $9.87B | $9.25B |
| YoY Revenue Growth % | +11.8% | +6.7% | — |
| Gross Profit | $3.67B | $3.24B | — |
| Gross Margin % | 33.2% | 32.9% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $1.56B | $1.35B | $1.26B |
| Operating Margin % | 14.1% | 13.6% | 13.6% |
| Net Income (GAAP) | $992.0M | $871.0M | $854.0M |
| EBITDA (Normalized) | $1.98B | $1.69B | $1.60B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $1.89B | $1.33B | $1.27B |
| Capital Expenditures (CapEx) | $527.0M | $425.0M | $416.3M |
| Free Cash Flow (FCF) | $1.36B | $909.0M | $855.7M |
| FCF Margin % | 12.3% | 9.2% | 9.2% |
| Return on Invested Capital (ROIC %) | 10.3% | 9.0% | 10.8% |
| Cash & Short-Term Equivalents | $420.0M | $549.0M | — |
| Total Debt (Short + Long Term) | $5.17B | $5.62B | $3.58B |
| Total Stockholders' Equity | $7.17B | $6.78B | $7.35B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR DGX.